New posts

Reply to thread

Message

up 7 per cent today...
.
financial results for the year ended 30 June 2024 and confirms its guidance for FY25 (consistent with its ASX announcement on 25 July 2024).

- Total Revenue of $45.4m; +69% growth on FY23 ($26.8m)
- EBITDA of $9.0m; +156% growth on FY23 ($3.5m)*
- 29 PhotonAssayTM units currently deployed and a strong pipeline of committed units
- 54 deployed or contractually-committed units, with one lease signed during FY24 and four further leases signed post-period
- Well positioned for ongoing global growth with $61.1m cash in bank and access to $95m of undrawn capital from Chrysos’ debt facility with the Commonwealth Bank of Australia

FY25 Guidance
- Total Revenue range of $60m to $70m
- EBITDA range of $9m to $19m
.
pedestrian... time to step up.

since listing
[ATTACH=full]183264[/ATTACH]
.
* I thought (brackets) meant a loss, not pcp (2023)

<blockquote data-quote="Dona Ferentes" data-source="post: 1294623" data-attributes="member: 66457">up 7 per cent today....financial results for the year ended 30 June 2024 and confirms its guidance for FY25 (consistent with its ASX announcement on 25 July 2024).- Total Revenue of $45.4m; +69% growth on FY23 ($26.8m)- EBITDA of $9.0m; +156% growth on FY23 ($3.5m)*- 29 PhotonAssayTM units currently deployed and a strong pipeline of committed units- 54 deployed or contractually-committed units, with one lease signed during FY24 and four further leases signed post-period- Well positioned for ongoing global growth with $61.1m cash in bank and access to $95m of undrawn capital from Chrysos’ debt facility with the Commonwealth Bank of Australia&nbsp;FY25 Guidance- Total Revenue range of $60m to $70m- EBITDA range of $9m to $19m.pedestrian... time to step up.since listing[ATTACH=full]183264[/ATTACH].* I thought (brackets) meant a loss, not pcp (2023)</blockquote>

[QUOTE="Dona Ferentes, post: 1294623, member: 66457"] [I]up 7 per cent today... .[/I] [B][COLOR=rgb(65, 168, 95)]financial results[/COLOR][/B] for the year ended 30 June 2024 and [B][COLOR=rgb(41, 105, 176)]confirms its guidance[/COLOR][/B] for FY25 (consistent with its ASX announcement on 25 July 2024). - Total Revenue of $45.4m; +69% growth on FY23 ($26.8m) - EBITDA of $9.0m; +156% growth on FY23 ($3.5m)* - 29 PhotonAssayTM units currently deployed and a strong pipeline of committed units - 54 deployed or contractually-committed units, with one lease signed during FY24 and four further leases signed post-period - Well positioned for ongoing global growth with $61.1m cash in bank and access to $95m of undrawn capital from Chrysos’ debt facility with the Commonwealth Bank of Australia [B]FY25 Guidance[/B] - Total Revenue range of $60m to $70m - EBITDA range of $9m to $19m . [I]pedestrian... time to step up. since listing [ATTACH type="full" alt="Screenshot_20240827-214024_CommSec.jpg"]183264[/ATTACH][/I] . *[I][SIZE=3] I thought (brackets) meant a loss, not pcp (2023)[/SIZE][/I] [/QUOTE]

Verification